Rare diseases
Investigational molecules
Locations
Back to Germany12 clinical trials in Coswig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study
GermanyStudy on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease
GermanyLong‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis
GermanyA study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis
GermanyA study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis
GermanyStudy of BI 765423 given by intravenous infusion for patients with idiopathic pulmonary fibrosis with or without standard treatment
GermanyStudy on the Effects of Inhaled Treprostinil for Patients with Progressive Pulmonary Fibrosis
GermanyStudy on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis
GermanyStudy on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases
GermanyStudy on the Effectiveness and Safety of LTP001 for Patients with Idiopathic Pulmonary Fibrosis
GermanyStudy on the Effects of Bexotegrast for Patients with Idiopathic Pulmonary Fibrosis
GermanyLong-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
GermanyThe busiest research cities in the country
What the registry says about research in the country
Ongoing clinical trials focusing on Progressive Pulmonary Fibrosis (PPF) and Idiopathic Pulmonary Fibrosis (IPF), evaluating innovative inhaled treatments to improve lung function and patient outcomes.
Multiple Phase 3 studies are examining both short and long-term treatment effects in patients with fibrotic conditions.
Research initiatives targeting Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), with trials designed to assess new therapeutic approaches for reducing lung function decline.
Comprehensive studies examining both established and experimental treatments for various forms of lung fibrosis.
Investigation of new compounds including bexotegrast and other innovative medications for treating various forms of pulmonary fibrosis and related conditions.
Multiple parallel studies are evaluating different therapeutic approaches to address various manifestations of fibrotic lung disease.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
